Obstet Gynecol Sci > Volume 65(4); 2022 > Article |
|
Ethical approval
The study protocol was approved by the Siriraj Institutional Review Board (SIRB) of the Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand (COA No. Si 060/2017).
Patient consent
All study participants provided written informed consent prior to enrollment. However, the use of images from patients are not required for the publication.
Author contributions
Nida Jareemit: Conceptualization, methodology, formal analysis, data curation, writing-original draft, writing-review and editing
Navin Horthongkham: Writing-review and editing
Suwanit Therasakvichya: Writing-review and editing
Boonlert Viriyapak: Writing-review and editing
Perapong Inthasorn: Writing-review and editing
Mongkol Benjapibal: Writing-review and editing
Vuthinun Achariyapota: Writing-review and editin
Irene Ruengkhachorn: Conceptualization, methodology, writing-review and editing
Type of HPV testing | Number of colposcopies | Sensitivity (% [95%CI]) | Specificity (% [95%CI]) | PPV(% [95%CI]) | NPV(% [95%CI]) | AUROC |
---|---|---|---|---|---|---|
No HPV testing | 318 (100.0) | |||||
HPV testinga) | 188 (59.1) | 78.9 (53.9-93) | 42.1 (36.5-47.9) | 8 (4.7-13) | 96.9 (91.8-99) | 0.60 (0.5-0.7) |
Partial HPV genotypingb) | 42 (13.2) | 10.5 (1.3-33.1) | 95.2 (92-97.4) | 13.3 (1.7-40.5) | 93.8 (90.3-96.4) | 0.53 (0.5-0.6) |
HPV genotypingc) | 142 (44.7) | 31.6 (12.6-56.6) | 59.9 (53.8-65.8) | 5.2 (1.9-11) | 92.6 (87.7-96) | 0.46 (0.35-0.57) |
P-value | <0.001 | 0.149 |
CIN2+, cervical intraepithelial neoplasia 2 or higher lesion; HPV, human papillomavirus; CI, confidence interval; PPV, positive predictive value; NPV, negative predictive value; AUROC, area under the receiver operating characteristic curve.
a) HPV testing was reported using two categories; negative 14 high-risk HPV or positive any of 14 high-risk HPV (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and/or 68);
Variable | LSIL histology (n=299) | HSIL histology (n=19) | P-value |
---|---|---|---|
Age (yr) | 0.649 | ||
<30 | 57 (96.6) | 2 (3.4) | |
30-49 | 193 (93.7) | 13 (6.3) | |
≥50 | 49 (92.5) | 4 (7.5) | |
Menopause status | 0.132 | ||
Pre-menopause | 269 (94.7) | 15 (5.3) | |
Menopause | 30 (88.2) | 4 (11.8) | |
Prior abnormal screening | 0.790 | ||
No or unknown | 221 (93.6) | 15 (6.4) | |
Yes | 78 (95.1) | 4 (4.9) | |
Colposcopic finding | 0.028a) | ||
Normal or low-grade lesion | 282 (94.9) | 15 (5.1) | |
High-grade lesion or cancer | 17 (81.0) | 4 (19.0) | |
HPV genotype | 0.097 | ||
Negative | 126 (96.9) | 4 (3.1) | |
Positive HPV non-16/18 | 58 (19.4) | 7 (36.8) | |
Positive HPV16/18 | 115 (38.5) | 8 (42.1) | |
Colposcopic finding with HPV status | <0.001a) | ||
Low grade lesion with HPV− | 117 (39.1) | 4 (21.1) | |
High grade lesion with HPV− | 9 (3.0) | 0 | |
Low grade lesion with HPV+ | 165 (55.2) | 11 (57.9) | |
High grade lesion with HPV+ | 8 (2.7) | 4 (21.1) | |
Number of high-risk HPV infections | 0.172 | ||
No HPV infection | 126 (96.9) | 4 (3.1) | |
Single infection | 117 (92.1) | 10 (7.9) | |
Multiple infections | 56 (91.8) | 5 (8.2) |